Shares of Retrophin, Inc. (RTRX) have traded between $10.87 – 24.7. The next earnings date is set for Feb 25, 2020. Let’s see how its prospects are shaping up.

What does Retrophin, Inc.(RTRX) do?

Retrophin, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

RTRX Insider Trading Insight

On 2020-01-07, Reed Elizabeth E SVP, GC, Corporate Secretary sold 1,500 shares of RTRX. That represents a value of $18,008. Not to be outdone, on 2020-01-07, Dube Eric M S – Sale sold7,500 shares of RTRX. These insiders are clearly in the know because they work closely with the company.

The NVRO Consensus Price Target

The mean recommendation of Nevro Corp. from top Wall Street analysts is a Moderate Buy. That is based on 7 analysts who work on the Street. Based on 7 analysts offering 12 month price targets for Nevro Crop in the last 3 months. The average price target is $110.17 with a high forecast of $132.00 and a low forecast of $88.00. The average price target represents a -9.56% decrease from the last price of $121.81. Last week, several articles were published in financial papers about NVRO and 38% Bearish while 62% Bullish.

NVRO Intraday Trading

NVRO is due to report earnings on Feb 20, 2020. In the last year the price has ranged from 41.25 – 124.84. Recently, Galligan Andrew H sold 2,782 shares of NVRO. He is a $2,128,086 shareholder in NVRO.

Looking for stocks similar to RTRX and NVRO?

Here are some stocks to consider: